NR4A1 and breast carcinoma: Most breast cancer cases in the United States are hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−), with higher percentages among male patients (78.3%–84.1%) versus female patients (66%–67.4%) [3–5].